Trial Profile
A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2021
Price :
$35
*
At a glance
- Drugs Cobitolimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms CONDUCT
- Sponsors InDex Pharmaceuticals
- 23 Aug 2021 According to an InDex Pharmaceuticals media release, the wo new employees have been appointed in the clinical development organisation in preparation of the start of this trial.
- 21 Nov 2020 This trial is Completed in Italy, according to European Clinical Trials Database record.
- 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020